FCRL2/FcRH2 Antibody [Unconjugated]

Human whole blood CD19 + B cells were stained with Goat Anti-Human FCRL2/FcRH2 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF2048) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108) and Human CD19 Phycoerythrin-conjugated Monoclonal Antibody (Catalog # FAB4867P). Quadrant markers were set based on control antibody staining (Catalog #AB‑108‑C).

• Reactivity: Hu
• Applications: WB, Flow, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

FCRL2/FcRH2 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human FCRL2/FcRH2
  Glu15-Asp395
  Accession # Q96LA5
• Specificity: Detects human FCRL2/FcRH2 in Western blots. In Western blots, approximately 20% cross-reactivity with recombinant human(rh) IRTA1 and IRTA5 is observed. Less than 6% cross-reactivity with rhIRTA3 and rhIRTA4 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FCRL2
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FCRL2/FcRH2 Antibody [Unconjugated]

• CD307b antigen
• CD307b
• Fc receptor homolog 2
• Fc receptor-like 2
• FcRH2
• FCRH2SPAP1B
• FCRL2
• FcR-like protein 2
• IFGP family protein 4
• IFGP4
• Immunoglobulin receptor translocation-associated protein 4
• immunoglobulin superfamily Fc receptor, gp42
• IRTA4
• IRTA4SPAP1C
• SH2 domain containing phosphatase anchor protein 1
• SH2 domain-containing phosphatase anchor protein 1Fc receptor-like protein 2
• SPAP1
• SPAP1A
• SPAP1immune receptor translocation-associated protein 4

Background

Fc receptor-like 2 (FCRL2), also known as FcRH2 and IRTA4, belongs to the family of glycoprotein homologs of classical immunoglobulin (Ig) Fc receptors. In human, the type I transmembrane FCRL protein family contains from three to nine immunoglobulin-like domains (1, 2). Mature human FcRH2 consists of a 382 amino acid (aa) extracellular domain (ECD) with four Ig-like C2-set domains, a 21 aa transmembrane segment, and an 86 aa cytoplasmic domain with one ITAM-like, and two ITIM-like motifs (3‑5). Alternate splicing of human FCRL2 may generate isoforms with N-terminal, internal, or C-terminal deletions (4, 5). The gene for FcRH2 maps to the human Iq21-23 locus which is a hotspot for chromosomal translocation events associated with B cell malignancies (3, 6). Although there are several Fc receptor‑like genes in the mouse, none of these is a clear ortholog to human FCRL2 (7). FCRL proteins are differentially expressed among B cells (2). FCRL2 is preferentially expressed on naïve and CD27⁺ memory B cells within the spleen, lymph nodes, tonsils, and peripheral blood (3, 4, 8, 9). It is also expressed on most B cells in B cell chronic lymphocytic leukemia (B‑CLL) patients (10). FCRL2 up‑regulation is associated with mutation of the immunoglobulin heavy chain variable (IGHV) and less aggressive forms of B-CLL (9, 11).

1. Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
2. Davis, R.S. et al. (2007) Annu. Rev. Immunol. 25:525.
3. Miller, I. et al. (2002) Blood 99:2662.
4. Davis, R.S. et al. (2001) Proc. Natl. Acad. Sci. 98:9772.
5. Xu, M.J. et al. (2001) Biochem. Biophys. Res. Commun. 280:768.
6. Hatzivassiliou, G. et al. (2001) Immunity 14:277.
7. Davis, R.S. et al. (2004) Int. Immunol. 16:1343.
8. Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
9. Huttmann, A. et al. (2006) Leukemia 20:1774.
10. Kazemi, T. et al. (2008) Int. J. Cancer 123:2113.
11. Li, F.J. et al. (2008) Blood 112:179.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FCRL2
• Uniprot:
  • Q96LA5()